Invest Now
Samco securities limited
Samco Star Rating Ads

Jagsonpal Pharmaceuticals Ltd

₹ 469.40 +3.30 (0.71%)

Updated on 11-10-2024 4:40 PM

Stock Rating

Pros 4

 

Cons 6

Price Performance

  • Day's Low
  • ₹458.1
  • Day's High
  • ₹474.8
₹ 469.4
  • 52-w low
  • ₹273.6
  • 52-w high
  • ₹495.6
469.4
  • Day's open
    ₹465
  • Previous close
    ₹466.100006
  • VWAP
    ₹467.39
  • Lower price band
    ₹375.55
  • Upper price band
    ₹563.25

Today's Market Action

The last traded share price of Jagsonpal Pharmaceuticals Ltd was 469.40 up by 0.71% on the NSE. Its last traded stock price on BSE was 470.40 up by 0.29%. The total volume of shares on NSE and BSE combined was 60,076 shares. Its total combined turnover was Rs 2.81 crores.

Medium and Long Term Market Action

Jagsonpal Pharmaceuticals Ltd hit a 52-week high of 495.6 on 09-10-2024 and a 52-week low of 273.6 on 27-03-2024. The stock price of Jagsonpal Pharmaceuticals Ltd is up by 17% over the last one month. It is up by 12.3% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

  • Market Cap (Cr): 1243

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About

Data not available.

FAQ's

What is Share Price of Jagsonpal Pharmaceuticals Ltd?

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?

What is PE Ratio of Jagsonpal Pharmaceuticals Ltd?

What is PB Ratio of Jagsonpal Pharmaceuticals Ltd?

What is the CAGR of Jagsonpal Pharmaceuticals Ltd?

How to Buy Jagsonpal Pharmaceuticals Ltd Share?

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

  • Great Cash Conversion of Profits
    The business has a great cash conversion ratio since it is able to convert a signifant portion of operating earnings of 106.06% into operating cash flow. This implies a great working capital cycle and large cash flows for either funding growth or dividends. This shall positively impact shareholder returns.
  • Asset Light Business
    The company operates a great asset light business with a high Asset turnover ratio of 24.56. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.
  • Zero Debt
    The company has almost nil to negligible debt to equity ratio of 0.05. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.
  • Strong Working Capital Cycle
    The company has a great working capital cycle of 43 days which results in lower investments in working capital and higher asset turnover. This reduces capital requirement of the business and drives RoE and cash flow generation positively. This is extremely positive for long term shareholders of the business.

Cons

  • Low Sustainable RoE
    The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
  • Low Return on Capital Employed
    The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
  • Highly Cyclical Industry
    The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
  • Low Pricing Power & High Competition
    The business has extremely low pricing power and is vulnerable to competitive pressure which can significantly impact shareholder returns.
  • Poor Capital Allocation
    The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 95.85 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
  • Negative Margin of Safety
    The relative margin of safety of investing in the company is low due to a recent sharp run up in stock prices.

Valuation Analysis

Margin of safety
(12/10/2024)
Stock Valuation
Yellow line
90
100.00%
100.00% People are bullish about Jagsonpal Pharmaceuticals Ltd
0.00%
0.00 % People are bearish about Jagsonpal Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Jagsonpal Pharmaceuticals Ltd

₹ 469.40 +3.30 (0.71%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      ×

      Filing Complaints on SCORES

      Easy & quick Easy & quick

      1. Register on SCORES portal

      2. Mandatory details for filling complaints on SCORES

      Name | PAN | Address | Mobile | Number | E-mail ID

      3. Benefits

      Effective Communication

      Speedy redressal of the grievances

      Website Icon